These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7690332)

  • 1. Interferon treatment of cutaneous T-cell lymphoma.
    Ross C; Tingsgaard P; Jørgensen H; Vejlsgaard GL
    Eur J Haematol; 1993 Aug; 51(2):63-72. PubMed ID: 7690332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
    Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
    Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
    J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.
    Rajan GP; Seifert B; Prümmer O; Joller-Jemelka HI; Burg G; Dummer R
    Arch Dermatol Res; 1996 Aug; 288(9):543-8. PubMed ID: 8874750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
    Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
    J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
    Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
    J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.
    Kuzel TM; Gilyon K; Springer E; Variakojis D; Kaul K; Bunn PA; Evans L; Roenigk HH; Rosen ST
    J Natl Cancer Inst; 1990 Feb; 82(3):203-7. PubMed ID: 2296050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons for cutaneous T-cell lymphoma monotherapy or combination with PUVA.
    Roenigk HH; Kuzel T; Rosen S
    Australas J Dermatol; 1993; 34(1):13-5. PubMed ID: 8240181
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon in the treatment of cutaneous T-cell lymphoma.
    Olsen EA; Bunn PA
    Hematol Oncol Clin North Am; 1995 Oct; 9(5):1089-107. PubMed ID: 8522486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon-alpha in cutaneous T-cell lymphoma].
    Knobler R
    Wien Med Wochenschr; 1993; 143(16-17):435-7. PubMed ID: 8273368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal combination with PUVA: rationale and clinical trial update.
    Stadler R
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
    Geskin L
    Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
    Seremet S; Abhyankar S; Herd TJ; Aires D
    J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
    Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
    Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic alternatives in cutaneous T-cell lymphoma.
    Holloway KB; Flowers FP; Ramos-Caro FA
    J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.